

FORM PTO-1449 (modified) To: U.S. Department of Commerce (P.W. FORM PAT-1449) Patent and Trademark Office <i>JUN 13 2005</i> INFORMATION DISCLOSURE STATEMENT BY APPLICANT					Atty. Dkt. No.	M#	Client Ref.
						051501-0305443	
					Applicant: Michael Croft, et al.		
					Appln. No.: 10/661,358		
					Filing Date: September 11, 2003		
					Examiner: Not yet assigned Group Art Unit: 1614		
Date: June 9, 2005					Page 1	Of 1	
U.S. PATENT DOCUMENTS							
Examiner's Initials*		Document Number	Date MM/YYYY	Name (Family Name of First Inventor)	Class	Sub Class	Filing Date (if appropriate)
<i>JO</i>	AR	5,759,546	06/1998	Weinberg, et al.	424	179.1	
	BR	6,312,700	11/2001	Weinberg	424	278.1	
	CR	6,566,082	05/2003	Weinberg, et al.	435	7.24	
	DR	US 2002/0054873 A1	05/2002	Weinberg	424	141.1	
FOREIGN PATENT DOCUMENTS							
		Document Number	Date MM/YYYY	Country	Inventor Name	English Abstract	Translation Readily Available
	ER	WO 95/21251	08/1995	WO	Weinberg, et al.		
	FR	WO 99/42585	08/1999	WO	Weinberg		
OTHER (including in this order Author, Title, Periodical Name, Date, Pertinent Pages, etc.)							
	GR	Evans, Dean E., et al., Engagement of OX40 Enhances Antigen-Specific CD4+ T Cell Mobilization/Memory Development and Humoral Immunity. Comparison of αOX-40 with αCTLA-4, <i>J. of Immunology</i> , 2001, 167:6804-6811.					
	HR	Gramaglia, Irene, et al., Ox-40 Ligand: A Potent Costimulatory Molecule for Sustaining Primary CD4 T Cell Responses, <i>J. of Immunology</i> , 1998, 161:6510-6517.					
	IR	Gramaglia, Irene, et al., The OX40 Costimulatory Receptor Determines the Development of CD4 Memory by Regulating Primary Clonal Expansion, <i>J. of Immunology</i> , 2000, 165:3043-3050.					
	JR	Kjaergaard, Jorgen, et al., Augmentation Versus Inhibition: Effects of Conjunctional OX-40 Receptor Monoclonal Antibody and IL-2 Treatment on Adoptive Immunotherapy of Advanced Tumor, <i>J. of Immunology</i> , 2001, 167: 6669-6677.					
	KR	Maxwell, Joseph R., et al., Danger and OX40 Receptor Signaling Synergize to Enhance Memory T Cell Survival by Inhibiting Peripheral Deletion, <i>J. of Immunology</i> , 2000, 164:107-112.					
	LR	Pan, Ping-Ying, OX40 Ligation Enhances Primary and Memory Cytotoxic T Lymphocyte Responses in an Immunotherapy for Hepatic Colon Metastases, <i>Molecular Therapy</i> , 6(4):528-536 (2002)					
<i>JO</i>	MR	Weatherill, Amy R., et al., OX40 Ligation Enhances Cell Cycle Turnover of Ag-Activated CD4 T Cell <i>in Vivo</i> , <i>Cellular Immunology</i> , 209, 63-75 (2001)					

Filia Aspenski 9/20/05

<i>JO</i>	NR	Weinberg, Andrew D., et al., Blocking OX-40/OX-40 Ligand Interaction In Vitro and In Vivo Leads to Decreased T Cell Function and Amelioration of Experimental Allergic Encephalomyelitis, <i>J. of Immunology</i> , 1999, 162: 1818-1826.				
<i>JO</i>	OR	Weinberg, Andrew D., Ox40: Targeted Immunotherapy-Implications for Tempering Autoimmunity and enhancing Vaccines, <i>TRENDS in Immunology</i> , 20(2):102-109 (February 2002)				
Examiner		<i>Dian Chaspeshi</i>	Date Considered: <i>9/20/05</i>			
<p>*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.</p>						